Esophagogastric Cancer

Oncology·MeSH: Neoplasm Metastasis

Prevalence

10.0 / 100K

Incidence

6.1 / 100K/yr

4 drugs in development·1 company·2 clinical trials

Drug Pipeline by Phase

Compare drugs

Amivantamab vs Amivantamab and Recombinant Human HyaluronidaseAmivantamab vs Amivantamab IVAmivantamab vs Amivantamab SC

Frequently asked questions

How many drugs are in development for Esophagogastric Cancer?

BioSniper tracks 4 drugs in development for Esophagogastric Cancer across 1 company.

How many clinical trials target Esophagogastric Cancer?

There are 2 clinical trials targeting Esophagogastric Cancer tracked by BioSniper.

What is the prevalence of Esophagogastric Cancer?

The estimated prevalence of Esophagogastric Cancer is approximately 10.0 per 100,000 population.

Deep-dive into Esophagogastric Cancer

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Esophagogastric Cancer — Drugs in Development & Clinical Trials | BioSniper